Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan;45(1):e16222.
doi: 10.1111/liv.16222.

Second-Line Treatment for Patients With Primary Biliary Cholangitis: A Systematic Review With Network Meta-Analysis

Edoardo G Giannini  1   2   3 , Andrea Pasta  1   2 , Francesco Calabrese  1   2 , Sara Labanca  1   2 , Simona Marenco  1   2 , Giulia Pieri  1   2 , Maria Corina Plaz Torres  1   2 , Mario Strazzabosco  3
Affiliations

Second-Line Treatment for Patients With Primary Biliary Cholangitis: A Systematic Review With Network Meta-Analysis

Edoardo G Giannini et al. Liver Int. 2025 Jan.

Abstract

Background & aims: Approximately 40% of patients with Primary Biliary Cholangitis (PBC) show incomplete response to ursodeoxycholic acid, thus needing second-line treatment to prevent disease progression. As no head-to-head comparison study is available, we used a network meta-analysis (NMA) to compare efficacy and safety of available second-line therapies.

Methods: We performed a systematic literature review including randomised, placebo-controlled trials of patients with PBC and incomplete response, or intolerance, to ursodeoxycholic acid, and compared relative risks (RRs) for primary (biochemical response at 52-week) and secondary outcomes [incidence of new-onset pruritus and serious adverse events (SAEs)].

Results: The NMA included three studies, each testing obeticholic acid (OCA), seladelpar or elafibranor versus placebo (active therapy/placebo: 379/191 patients). All treatments significantly increased the RR for biochemical response with an advantage of elafibranor versus seladelpar (RR: 4.37, 95% CI: 1.01-18.87). OCA 5-10 mg/10 mg was associated with a higher risk of new-onset pruritus compared to placebo (RR: 1.43; 95% CI: 1.09-1.88/RR: 1.79; 95% CI: 1.37-2.33), while seladelpar decreased this risk (RR: 0.30; 95% CI: 0.12-0.80). Compared to placebo, OCA 5-10 mg/10 mg was associated with an increased risk of SAE (RR: 3.82; 95% CI: 1.46-10.02/RR 2.67; 95% CI: 1.00-7.08).

Conclusions: Among second line therapies for patients with PBC, elafibranor is slightly more effective in obtaining biochemical response than seladelpar that, on the other hand, is the only drug associated with a lower incidence of pruritus. While of similar efficacy, OCA was associated with increased pruritus and SAEs. These findings may help personalise second-line treatment in patients with PBC.

Keywords: bezafibrate; elafibranor; obeticholic acid; response; seladelpar; treatment; ursodeoxycholic acid.

PubMed Disclaimer

Conflict of interest statement

Edoardo G. Giannini reports speaking and teaching for AbbVie, AstraZeneca, Eisai, Gilead, Roche; advising for AstraZeneca, Eisai, Gilead, Ipsen, Roche. Sara Labanca speaking and teaching for Advanz, Gilead, Ipsen. Simona Marenco speaking and teaching for Ipsen. Mario Strazzabosco advises for Engitix. Andrea Pasta, Francesco Calabrese, Giulia Pieri and Maria Corina Plaz Torres have no conflicts of interest to declare.

Figures

FIGURE 1
FIGURE 1
Forest plot reporting the relative risk (A) and the risk difference (B) of biochemical response after 12‐month of treatment with the various drugs.
FIGURE 2
FIGURE 2
Forest plot showing the relative risk (A) and risk difference (B) for new‐onset pruritus within 12‐month of treatment with the various drugs.
See this image and copyright information in PMC

Similar articles

  • Ursodeoxycholic acid for primary biliary cirrhosis.
    Rudic JS, Poropat G, Krstic MN, Bjelakovic G, Gluud C. Rudic JS, et al. Cochrane Database Syst Rev. 2012 Dec 12;12(12):CD000551. doi: 10.1002/14651858.CD000551.pub3. Cochrane Database Syst Rev. 2012. PMID: 23235576 Free PMC article.
  • Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis.
    Kowdley KV, Bowlus CL, Levy C, Akarca US, Alvares-da-Silva MR, Andreone P, Arrese M, Corpechot C, Francque SM, Heneghan MA, Invernizzi P, Jones D, Kruger FC, Lawitz E, Mayo MJ, Shiffman ML, Swain MG, Valera JM, Vargas V, Vierling JM, Villamil A, Addy C, Dietrich J, Germain JM, Mazain S, Rafailovic D, Taddé B, Miller B, Shu J, Zein CO, Schattenberg JM; ELATIVE Study Investigators’ Group; ELATIVE Study Investigators' Group. Kowdley KV, et al. N Engl J Med. 2024 Feb 29;390(9):795-805. doi: 10.1056/NEJMoa2306185. Epub 2023 Nov 13. N Engl J Med. 2024. PMID: 37962077 Clinical Trial.
  • Review of Current and Upcoming Second-Line Treatments for Primary Biliary Cholangitis.
    Cumpian NA, Choi G, Saab S. Cumpian NA, et al. Dig Dis Sci. 2025 Jan;70(1):100-110. doi: 10.1007/s10620-024-08742-w. Epub 2024 Dec 2. Dig Dis Sci. 2025. PMID: 39621183
  • Pharmacological interventions for primary biliary cholangitis: an attempted network meta-analysis.
    Saffioti F, Gurusamy KS, Eusebi LH, Tsochatzis E, Davidson BR, Thorburn D. Saffioti F, et al. Cochrane Database Syst Rev. 2017 Mar 28;3(3):CD011648. doi: 10.1002/14651858.CD011648.pub2. Cochrane Database Syst Rev. 2017. PMID: 28350426 Free PMC article.
  • A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis.
    Hirschfield GM, Bowlus CL, Mayo MJ, Kremer AE, Vierling JM, Kowdley KV, Levy C, Villamil A, Ladrón de Guevara Cetina AL, Janczewska E, Zigmond E, Jeong SH, Yilmaz Y, Kallis Y, Corpechot C, Buggisch P, Invernizzi P, Londoño Hurtado MC, Bergheanu S, Yang K, Choi YJ, Crittenden DB, McWherter CA; RESPONSE Study Group. Hirschfield GM, et al. N Engl J Med. 2024 Feb 29;390(9):783-794. doi: 10.1056/NEJMoa2312100. Epub 2024 Feb 21. N Engl J Med. 2024. PMID: 38381664 Clinical Trial.
See all similar articles

Cited by

References

    1. Colapietro F., Bertazzoni A., and Lleo A., “Contemporary Epidemiology of Primary Biliary Cholangitis,” Clinics in Liver Disease 26, no. 4 (2022): 555–570. - PubMed
    1. Gerussi A., Cristoferi L., Carbone M., Asselta R., and Invernizzi P., “The Immunobiology of Female Predominance in Primary Biliary Cholangitis,” Journal of Autoimmunity 95 (2018): 124–132. - PubMed
    1. Trivella J., John B. V., and Levy C., “Primary Biliary Colangitis: Epidemiology, Prognosis, and Treatment,” Hepatology Communications 7, no. 6 (2023): e0179. - PMC - PubMed
    1. Corpechot C., Abenavoli L., Rabahi N., et al., “Biochemical Response to Ursodeoxycholic Acid and Long‐Term Prognosis in Primary Biliary Cirrhosis,” Hepatology 48, no. 3 (2008): 871–877. - PubMed
    1. Corpechot C., Carrat F., Bonnand A. M., Poupon R. E., and Poupon R., “The Effect of Ursodeoxycholic Acid Therapy on Liver Fibrosis Progression in Primary Biliary Cirrhosis,” Hepatology 32, no. 6 (2000): 1196–1199. - PubMed

Publication types

MeSH terms

Substances